Drug R&D Models Will Change Drastically By 2020, PwC Report Predicts
Executive Summary
The pharmaceutical industry is about to face a world in which successful companies no longer focus on blockbusters, drugs are approved in stages for an ever widening patient population, and large sales teams have been replaced by advisers, according to a report by PricewaterhouseCooper
You may also be interested in...
Lilly Sings A New Tune: Chorus Unit Brings High Efficiency Note To Early R&D
Lilly's independently operating Chorus drug development unit has created a means to mitigate the risk of drug development by conducting small-scale, targeted experiments separate from the larger R&D organization
PDUFA Provides Opportunity For Conditional Approvals, Consumer Groups Say
Consumer groups are advocating the creation of a "conditional" approval authority for FDA through the reauthorization of the Prescription Drug User Fee Act
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.